Modulation of the mineralocorticoid receptor as add-on treatment in depression: a randomized, double-blind, placebo-controlled proof-of-concept study.
about
The ubiquitous mineralocorticoid receptor: clinical implicationsBrain mineralocorticoid receptors in cognition and cardiovascular homeostasisGenetic Moderation of Stress Effects on Corticolimbic CircuitryCortisol's effects on hippocampal activation in depressed patients are related to alterations in memory formationBiomarkers for depression: recent insights, current challenges and future prospects.The role of mineralocorticoid receptor function in treatment-resistant depression.Mineralocorticoid receptors in the brain and cardiovascular regulation: minority rule?Chronic overexpression of corticotropin-releasing factor from the central amygdala produces HPA axis hyperactivity and behavioral anxiety associated with gene-expression changes in the hippocampus and paraventricular nucleus of the hypothalamus.A randomized trial on mineralocorticoid receptor blockade in men: effects on stress responses, selective attention, and memory.Mineralocorticoid receptor stimulation improves cognitive function and decreases cortisol secretion in depressed patients and healthy individualsA common and functional mineralocorticoid receptor haplotype enhances optimism and protects against depression in females.The multifaceted mineralocorticoid receptorAngiotensin II AT(1) receptor blockers as treatments for inflammatory brain disorders.Third-generation Mineralocorticoid Receptor Antagonists: Why Do We Need a Fourth?The prednisolone suppression test in depression: dose-response and changes with antidepressant treatmentUse of Salivary Diurnal Cortisol as an Outcome Measure in Randomised Controlled Trials: a Systematic ReviewThe mineralocorticoid receptor agonist, fludrocortisone, differentially inhibits pituitary-adrenal activity in humans with psychotic major depression.Blocking mineralocorticoid receptors impairs, blocking glucocorticoid receptors enhances memory retrieval in humans.Metyrapone in treatment-resistant depression.Early Life Stress in Depressive Patients: HPA Axis Response to GR and MR Agonist.HPA axis in major depression: cortisol, clinical symptomatology and genetic variation predict cognition.HPA axis alterations in mental disorders: impact on memory and its relevance for therapeutic interventions.Role of mineralocorticoid receptors on the hypothalamus-pituitary-adrenal axis in humans.Corticosteroid receptor signalling modes and stress adaptation in the brain.Stress and Depression: a Crucial Role of the Mineralocorticoid Receptor.Assessment of the hypothalamic-pituitary-adrenal axis activity: glucocorticoid receptor and mineralocorticoid receptor function in depression with early life stress - a systematic review.Association between cortisol awakening response and memory function in major depression.Gender differences in anxiety and depressive symptoms in patients with primary hyperaldosteronism: a cross-sectional study.Depression and the hypothalamic-pituitary-adrenal axis: increasing the scope.
P2860
Q26861721-EB90C6D5-5FDA-4EBD-B149-1F7C842FF57FQ26995642-400B4B4A-DEB2-4632-A1C5-41F0EED40576Q28606435-9703A2E2-F6F5-46E8-988B-3CD581B458F6Q30498379-9857246B-8F8B-4693-9167-F4069EE7691FQ33704099-56B0ABFD-5943-49D2-8BBD-AE75BD852902Q34361037-C7C55D77-03DD-4741-A2FC-C23B79A91CF4Q35118620-DA1035D2-A219-4CF2-8C8B-8BF98AA62799Q35190097-CA87B853-2F25-4E54-9BFF-5B53D5C6E938Q35592045-B9E22513-C8BA-4277-A1BF-FE8B5A185A53Q35647316-9206C6B0-014B-4C68-A30D-FC5503DDB2A0Q35844146-9B6D9213-1474-4455-A5E9-55671C2D8F06Q35906989-8FA6791D-4F21-43BC-B92D-4DE2489CAD96Q36410269-137C709D-074C-4545-AA0A-7BED3933570DQ36437145-628D272D-D610-46AA-9857-17628DB54F37Q36442015-260FEB5F-809F-4397-8118-291E8E6997C1Q36772974-8EF057C5-FBF3-4A4B-93EA-BDD49FD27BE3Q36787614-170FBD33-53CB-4E6C-83CF-2610C3E5758EQ36901146-E5CA8794-F0CD-4C15-B73E-D78885F7157CQ37079032-7A5A8A5C-C1D1-4236-8F17-360C776E4A6BQ37510945-2CEBDAF6-7E71-476D-B72C-C7EA280ECA75Q37647371-EAADFEFD-71A2-4DAF-B358-2A28A8B482FFQ37818507-D6BD6C06-BA3B-4239-9C32-B220760BD368Q38029960-B7A68E2A-07A4-47E4-83ED-72454AA2C7C0Q38471565-D788CE13-B567-4F66-B919-6B91F78B9CC1Q38771510-E6E5501C-8B5B-44A5-BCC1-781CF1F737BCQ39128695-F2B84A5C-DD02-4E01-BF4B-4DCF75AF3A78Q48148070-CE219F94-D915-4524-8EEE-E491AB62CE12Q48684809-65483E04-992E-4500-B14A-E372EEC41BBCQ48742074-2BF45B10-3196-4136-988F-16DA8F04E2EE
P2860
Modulation of the mineralocorticoid receptor as add-on treatment in depression: a randomized, double-blind, placebo-controlled proof-of-concept study.
description
2009 nî lūn-bûn
@nan
2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Modulation of the mineralocort ...... rolled proof-of-concept study.
@ast
Modulation of the mineralocort ...... rolled proof-of-concept study.
@en
type
label
Modulation of the mineralocort ...... rolled proof-of-concept study.
@ast
Modulation of the mineralocort ...... rolled proof-of-concept study.
@en
prefLabel
Modulation of the mineralocort ...... rolled proof-of-concept study.
@ast
Modulation of the mineralocort ...... rolled proof-of-concept study.
@en
P2093
P50
P1476
Modulation of the mineralocort ...... rolled proof-of-concept study.
@en
P2093
Alexander Yassouridis
Kim Hinkelmann
Klaus Wiedemann
Michael Kellner
P304
P356
10.1016/J.JPSYCHIRES.2009.10.006
P577
2009-11-11T00:00:00Z